10x Genomics Inc., founded in 2012 and headquartered in Pleasanton, California, United States, provides advanced genomic analysis systems that focus on single-cell and spatial genomics. The company’s primary revenue comes from its flagship Chromium system and recurring consumable sales, supporting cutting-edge research across academic and clinical settings. Led by CEO Serge Saxena since 2019, it holds a strong market position with significant technological advantages. Future growth is being driven by innovations in next-generation platforms and expanded market strategies.
Item 5 (Issuer Purchases of Equity Securities) of the FY2025 10-K states "None"; the company has no share repurchase program.
For the years ended December 31, 2025, 2024, and 2023, no single customer represented more than 10% of revenue.